This two-part program, produced in collaboration with Radcliffe Cardiology, considers the guideline-directed approach to chronic kidney disease (CKD) and how SGLT-2 inhibitors can be used to maximal effect. The webinars are chaired by Professor James Burton, MD (University of Leicester, United Kingdom), with expert insight from world-renowned faculty Professor David Wheeler, MD (University College London, UK), Professor Navdeep Tangri, MD (University of Manitoba, Canada), and Professor Carol Pollock, MD (University of Sydney, Australia).
Part 2 of this dynamic series offers a forensic analysis of current practices, revisiting the patient case from Part 1 in reflection of expected guideline updates. The panel provides evidence-based strategies for initiating pharmacological therapies that transcend the theoretical and become actionable in everyday practice.